Deals
Medicines and Mines Help Dealmakers Defy $900 Billion M&A Slump
- Novartis, Glencore among names involved in Merger Monday
- Treatment of rare diseases, clean energy shift driving deals
This article is for subscribers only.
The hunt for medicines to treat rare diseases and a flurry of mining deals are again providing respite to the slump in mergers and acquisitions.
With global transaction values standing at $1.1 trillion this year — about $900 billion less than at this point in 2022 — just a handful of industries are keeping dealmakers busy.